NCT00927823View on ClinicalTrials.gov

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

April 30, 2012

Conditions
Cancer
Interventions
DRUG

PF-04691502

Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.

Trial Locations (7)

14221

Pfizer Investigational Site, Amherst

14263

Pfizer Investigational Site, Buffalo

48201

Pfizer Investigational Site, Detroit

90095

Pfizer Investigational Site, Los Angeles

90404

Pfizer Investigational Site, Los Angeles

Pfizer Investigational Site, Santa Monica

90095-6984

Pfizer Investigational Site, Los Angeles

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00927823 - A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients | Biotech Hunter | Biotech Hunter